Topic Editors

Prof. Dr. Roman Blaheta
Department of Urology, Goethe-University Frankfurt, Interdisciplinary Science Building, Building 25A, Room 404, Theodor-Stern-Kai 7, D-60590 Frankfurt / Main, Germany
Prof. Dr. Beatrice E. Bachmeier
Dr.-Willmar-Schwabe Endowed Professorship for Health Service Research - Core Area Phytopharmaceuticals, Institute of Pharmaceutical Biology, Goethe-University, 60438 Frankfurt, Germany

Novel Approaches in Bladder Cancer Treatment

Abstract submission deadline
closed (30 April 2022)
Manuscript submission deadline
31 July 2022
Viewed by
654

Topic Information

Dear Colleagues,

Bladder cancer is the ninth most common malignant ailment and the fourteenth most common cause of cancer death worldwide. Over the past decades, novel and potent agents have been developed and approved. However, although innovative approaches, such as targeted therapy and/or immunotherapy, have provided benefits for tumor patients, many challenges, such as low response rate and drug resistance, remain overt. Extensive research is required to refine and optimize the current bladder cancer treatment protocols. Dissatisfaction with the conventional treatment has meanwhile driven many cancer patients to seek “non-conventional” care options, including natural products, mind and body practices, or other non-conventional health approaches. From the scientists’ side, innovative and “risky” projects are under investigation focusing on cancer stem cell targeting, selective photodynamic technology, or anticancer vaccine therapy, among others. The purpose of this Special Issue is to collect original research articles and reviews on non-conventional medicine for bladder cancer. Both clinical trials and preclinical studies (in vitro and in vivo) are welcome that do not reflect the mainstream of cancer treatment but which are rather original and may open the mind for unconventional strategies.

Prof. Dr. Roman Blaheta
Prof. Dr. Beatrice E. Bachmeier
Topic Editors

Keywords

  • bladder cancer
  • non-mainstream treatment
  • complementary medicine
  • plant compounds
  • stem cell targeting
  • anticancer vaccination
  • photodynamic therapy

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomolecules
biomolecules
4.879 3.2 2011 16.4 Days 2100 CHF Submit
Cancers
cancers
6.639 4.4 2009 18.5 Days 2400 CHF Submit
Current Oncology
curroncol
3.677 3.8 1994 22 Days 1800 CHF Submit
International Journal of Molecular Sciences
ijms
5.924 6.0 2000 16.1 Days 2300 CHF Submit
Onco
onco
- - 2021 15.0 days * 1000 CHF Submit

* Median value for all MDPI journals in the second half of 2021.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:
Communication
Gold Glyconanoparticles Combined with 91–99 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder Tumors
Cancers 2022, 14(10), 2413; https://doi.org/10.3390/cancers14102413 - 13 May 2022
Abstract
This study presents proof of concept assays to validate gold nanoparticles loaded with the bacterial peptide 91–99 of the listeriolysin O toxin (GNP-LLO91–99 nanovaccines) as immunotherapy for bladder tumors. GNP-LLO91–99 nanovaccines showed adjuvant abilities as they induce maturation and activation of [...] Read more.
This study presents proof of concept assays to validate gold nanoparticles loaded with the bacterial peptide 91–99 of the listeriolysin O toxin (GNP-LLO91–99 nanovaccines) as immunotherapy for bladder tumors. GNP-LLO91–99 nanovaccines showed adjuvant abilities as they induce maturation and activation of monocyte-derived dendritic cells (MoDCs) to functional antigen-presenting cells in healthy donors and patients with melanoma or bladder cancer (BC), promoting a Th1 cytokine pattern. GNP-LLO91–99 nanovaccines were also efficient dendritic cell inducers of immunogenic tumor death using different bladder and melanoma tumor cell lines. The establishment of a pre-clinical mice model of subcutaneous BC confirmed that a single dose of GNP-LLO91–99 nanovaccines reduced tumor burden 4.7-fold and stimulated systemic Th1-type immune responses. Proof of concept assays validated GNP-LLO91–99 nanovaccines as immunotherapy by comparison to anti-CTLA-4 or anti-PD-1 antibodies. In fact, GNP-LLO91–99 nanovaccines increased percentages of CD4+ and CD8+ T cells, B cells, and functional antigen-presenting DCs in tumor-infiltrated lymphocytes, while they reduced the levels of myeloid-derived suppressor cells (MDSC) and suppressor T cells (Treg). We conclude that GNP-LLO91–99 nanovaccines can work as monotherapies or combinatory immunotherapies with anti-CTLA-4 or anti-PD-1 antibodies for solid tumors with high T cell infiltration, such as bladder cancer or melanoma. Full article
(This article belongs to the Topic Novel Approaches in Bladder Cancer Treatment)
Show Figures

Graphical abstract

Back to TopTop